Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug
January 20, 2023 at 09:23 AM EST
The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following